Appointment of Chief Financial Officer

RNS Number : 4510B

Shield Therapeutics PLC

04 April 2017

 

Shield Therapeutics plc

("Shield" or the "Group")

Appointment of Chief Financial Officer

London, UK, 4 April 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, today announces that Joanne Estell will join the Group as Chief Financial Officer and Board member on 1^st May 2017.

Joanne joins Shield with more than 20 years' experience in senior finance, strategy and M&A positions.  Most recently, she was Chief Financial Officer and Company Secretary of Stadium Group Plc, an AIM-listed global manufacturer of technology led products.  Prior to this, Joanne was Head of Mergers & Acquisitions at Survitec Group Ltd, a manufacturing company with approximately $400m of annual revenues and more than 2,000 staff.  Having started her career as a finance professional with Whitbread plc, she also held various senior positions at Smiths Group, the FTSE 100 global technology company, from 2001 to 2011, culminating as Finance Director of their John Crane Global Specialised Business division.

Commenting on the appointment, Carl Sterritt, Founder and Chief Executive Officer of Shield Therapeutics, said: "Joanne has an exceptional track record and I am delighted to welcome her to Shield Therapeutics as our CFO.  She brings a wealth of finance experience from listed international businesses and has strong ambitions that are aligned with ours.  Having evaluated, developed and delivered corporate growth strategies, the Board and I are particularly looking forward to working closely with Joanne as she plays a pivotal role in Shield's ongoing journey towards becoming a fully-fledged, international and commercially-focused specialty pharmaceutical business."

Joanne Estell added: "I am delighted to be joining Shield Therapeutics at this exciting time in its rapid development.  With Feraccru now firmly on the market, Shield is delivering growing revenues and expanding its reach within existing markets as well as planning for further international expansion.  By working closely with Carl and Shield's highly experienced and driven wider team, my focus will be on effectively supporting our ambitious growth plans so we can deliver increasing value to our shareholders."

Joanne Estell, age 45, is currently a director of the following companies:

Current Directorships: 

210 St Margaret's Road Twickenham Limited (Dormant)

Previous Directorships:

Stadium Group Plc

Stadium Power Limited

Stadium IGT Limited

Stadium United Wireless Limited

Stontronics Limited

Zirkon Holdings Limited

Stadium Zirkon UK Limited

Hale End Holdings Limited

Stadium Wireless Devices Limited

Stadium Electronics Limited

Stadium Electrical Holdings Limited

Valuegolden Limited

Kingslo Limited

KRP Power Source (UK) Limited

Fox Industries Limited

Ferrus Power Limited

Stadium Asia Limited (Incorporated in British Virgin Islands, registered in Hong Kong)

Dongguan Arlec Electrical Products Co. Limited (China)

Shanghai Hongbain Electronics Company Limited (China)

STMC Limited (Hong Kong)

Ying Si Ke Electrical Products Co. Limited (China) SGW Sweden AB

- Ends -

For further information please contact:

Shield Therapeutics plc	[phone]
Carl Sterritt, Chief Executive Officer
Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce	[phone]
Financial PR Advisor Consilium Strategic Communications	[phone] [e-mail]
Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until mid 2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.

 

END

 

 

BOAFMGGDGFVGNZZ